TGFB1 and neoplasm: As we all know, apart from RT, some other tumor therapies may also face the acquired immune resistance of PD‐L1 and TGF‐β protein upregulation, including 5‐fluorouracil, and cisplatin‐based‐chemotherapy, adoptive cell therapy, oncolytic virus therapy, and bacteria therapy.[14, 27] IR‐TAM@Alb may also be used as ideal adjuvant therapy to sensitize these tumor therapies via PD‐L1 and TGF‐β dual‐immune checkpoint inhibition (Figures 1, 2, 3, 4, 5, 6).